Active Ingredient History
Teplizumab is a humanized anti-CD3 monoclonal antibody that is being evaluated for treatment and prevention of type 1 diabetes mellitus (T1DM) by the biopharmaceutical company Provention Bio. Teplizumab has also been evaluated for treatment of renal allograft rejection, for induction therapy in islet transplant recipients, and for psoriatic arthritis. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Arthritis, Psoriatic (Phase 2)
Autoimmune Diseases (Phase 2)
Diabetes Mellitus, Experimental (Phase 1/Phase 2)
Diabetes Mellitus, Type 1 (Phase 3)
Glucose Intolerance (Phase 2)
Hepatitis C, Chronic (Phase 2)
Hypoglycemia (Phase 1/Phase 2)
Islets of Langerhans Transplantation (Phase 1/Phase 2)
Melanoma (Phase 1)
Psoriasis (Phase 1/Phase 2)
Transplantation, Homologous (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue